PRP-2019 Adjuvant Antibiotic Technology
Unlocking Strategies to Combat Bacterial Resistance to Antibiotics
Transmission electron microscopy reveals multi drug-resistant P.aeruginosa membrane lysis when exposed to a combination of adjuvant antibiotic and commercial ciprofloxacin. © Polyamyna
Problem
Managing infectious diseases has become an escalating global challenge, largely attributed to the emergence and rapid dissemination of antibiotic resistance among pathogenic microorganisms. The 2016–2017 report by the WHO’s Global Antimicrobial Surveillance System (GLASS) underscored this issue across various regions worldwide, revealing widespread multi-drug resistance in diverse infectious agents.
Consequently, a rising number of infections are proving difficult, if not impossible, to treat, resulting in elevated morbidity and mortality rates. Urgent action is imperative to develop new antibiotics. However, conventional drug discovery and development pipelines have made limited strides in yielding novel therapeutics capable of effectively combating these emergent pathogens.
Solution
Strategy for Antibiotic Development
The strategy involves not only discovering new antibiotics but also revitalizing existing ones.
Adjuvants Development
Adjuvants are being developed to enhance the effectiveness of antibiotics.
Polyamyna's Lead Molecules
Polyamyna has identified and refined lead molecules that can overcome bacterial resistance across various antibiotic classes.
Validation
These compounds have undergone rigorous validation, showing potent adjuvant activity against antibiotic-resistant bacteria in both laboratory (in-vitro) and worm model (in-vivo) studies.
Antimicrobial Peptide PRP-2019
Evaluation of PRP-2019 revealed its efficacy in clearing multi-drug resistant E.coli infections in Galleria mellonella infection models when combined with Erythromycin, which the pathogen was resistant to.
Promising Potential
This innovation shows promising potential for treating infections caused by antibiotic-resistant bacteria by combining these adjuvant compounds with antibiotics.
Repurposing Discontinued Drugs
These compounds also hold promise for repurposing and rejuvenating discontinued drugs that have become ineffective against antibiotic-resistant infections.
Application
Co-administration with antibiotics to combat drug-resistant bacteria.
Advantages
- Effective against a broad spectrum of drug-resistant bacteria.
- Enables reintroduction of outdated antibiotics by breaking resistance to established drugs.
- Synergistic action with multiple classes of antibiotics.
- Demonstrates high potency and low toxicity.
- Minimizes selection pressure, as compounds do not directly kill bacteria.
- Anticipates low rates of resistance development, given the conservation of putative bacterial targets.
- Offers numerous analogues for further development.